UK ad review
This article was originally published in The Tan Sheet
Executive Summary
The UK's Medicines & Healthcare products Regulatory Agency will review promotional materials for all newly licensed medicines before the advertisements are run, the agency announces Nov. 8. While MHRA previously only reviewed ads for some new ads based on risk, vetting advertising material on all new drugs allows the agency to "provide an additional safeguard to ensure that healthcare professionals and the public are not misled." Review time for promotional materials is expected to last between three and six months "but could take longer should any problems be identified," the agency stated. In the U.S., direct-to-consumer advertising guidelines released in August by the Pharmaceutical Research & Manufacturers of America called for manufacturers to submit advertising materials to FDA prior to launch (1"The Tan Sheet" Aug. 22, 2005, p. 7). EU legislation prohibits direct-to-consumer advertising for conditions including insomnia, diabetes and other metabolic diseases, serious infectious diseases including HIV-related diseases and tuberculosis...
You may also be interested in...
PhRMA Guidelines May Redraw Line Between DTC, OTC Advertising
Pfizer direct-to-consumer prescription drug ads will "clearly indicate... that the medicine is a prescription medicine," the firm said in an Aug. 11 announcement of planned DTC changes
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.